Prevalence and influencing factors of chronic hepatitis B virus infection complicated with chronic kidney disease

doi:10.3877/cma.j.issn.1674-1358.2018.05.002

Abstract

Abstract:

Objective

To investigate the prevalence and influencing factors of chronic hepatitis B virus (HBV) infection complicated with chronic kidney disease.

Methods

From July 2016 to July 2017, the patients with chronic HBV infection were selected from Beijing Ditan Hospital, Capital Medical University. According to the serum creatinine (Scr) level and age of the subjects, the MDRD-equation was used to calculate the glomerular filtration rate (GFR) of the patients, and the prevalence rate of chronic kidney disease in the target population was estimated and the risk factors affecting the prevalence were analyzed.

Results

Total of 6 665 patients with chronic HBV infection were collected, including 4 457 males and 2 208 females; 607 HBV carriers, 4 630 patients with chronic hepatitis B and 1 428 patients with liver cirrhosis after hepatitis B. The prevalence rate of chronic kidney disease (CKD) in patients with eGFR < 60 ml/min/1.73 m²and 60≤eGFR < 90ml/min/1.73 m²were 72 cases (1.08%) and 586 cases (8.79%), respectively, which was higher of male patients than that of women, but with no significant differences (χ²= 0.52,P = 0.473). The prevalence of CKD increased with age increasing and the difference was significant among patients with different ages (χ²= 356.71,P< 0.001). The prevalence rate of CKD in patients with cirrhosis (3.15%) was significantly higher than that in patients of HBV carrier (0.16%) and chronic hepatitis B (0.59%), with significant difference (χ²= 144.00, P< 0.001).

Conclusions

Chronic HBV infection is associated with disease progression and CKD prevalence. Age, cirrhosis, hypertension and diabetes are all independent risk factors for CKD in patients with chronic HBV infection.

Key words: Chronic hepatitis B virus infection, Chronic kidney disease, Estimated glomerular filtration rate, Prevalence, Risk factor

Ying Duan, Xiaomei Wang, Yingying Zhao, Ben Li, Min Quan, Weini Ou, Huichun Xing. Prevalence and influencing factors of chronic hepatitis B virus infection complicated with chronic kidney disease[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(05): 422-426.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.05.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I05/422

Figures/Tables 4

References 26

[1]	顾天翊,陆伦根.肝硬化并发多器官功能障碍的发病机制与治疗方案[J].临床肝胆病杂志,2017,33(6):1165-1168.
[2]	中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].中华肝脏病杂志,2015,23(12):888-905.
[3]	Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med,2013,158(11):825-830.
[4]	Kuo CF, Yu KH, Shen YM, et al. The Chinese version of the modification of diet in renal disease (MDRD) equation is a superior screening tool for chronic kidney disease among middle-aged Taiwanese than the original MDRD and Cockcroft-Gault equations[J]. Biomed J,2014,37(6):398-405.
[5]	刘玉梅,汪年松.规范乙型肝炎病毒相关性肾小球肾炎的诊断和治疗[J].临床肾脏病杂志,2014,14(4):249-252.
[6]	Fabrizi F, Donato FM, Messa P. Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis[J]. Ann Hepatol,2017,16(1):21-47.
[7]	彭阿平,朱萱.肝肾综合征的发病机制及诊治的研究进展[J].世界华人消化杂志,2015,23(9):1440-1446.
[8]	史浩,陈楠,张文,等.简化MDRD公式预测慢性肾病患者肾小球滤过率的应用评价及校正[J].中国实用内科杂志(临床版),2006,26(9):665-669.
[9]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet,2012,379(9818):815-822.
[10]	Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med,2016,375(9):905-906.
[11]	霍娜,陆海英,王贵强,等.长期应用核苷(酸)类药物治疗对慢乙肝患者肾功能的影响[J].中国临床药理学与治疗学,2017,22(9):1029-1034.
[12]	余晓阳,赵守松.核苷酸类抗病毒药物经治慢性乙肝患者肾功能调查及其危险因素分析[J].山西医科大学学报,2016,47(11):968-972.
[13]	Park J, Jung KS, Lee HW, et al. Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis[J]. Gut Liver,2017,11(6):828-834.
[14]	Shin JH, Kwon HJ, Jang HR, et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents[J]. Medicine (Baltimore),2016,95(1):e2400.
[15]	那妍,娄宪芝.替比夫定与阿德福韦酯治疗对慢性乙型肝炎患者肾脏功能影响的比较[J].中国医科大学学报,2014,43(5):446-448.
[16]	韩晓颖,陈秀记,闫泽强,等.替比夫定和拉米夫定对乙肝患者肾脏影响的研究[J].国际病毒学杂志,2016,23(3):197-199.
[17]	王美玲.替比夫定治疗慢性乙肝对肾功能的近远期影响[J].世界临床医学,2017,11(23):89.
[18]	Luo Q, Deng Y, Cheng F, et al. Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis[J]. Medicine (Baltimore),2016,95(50):e5578.
[19]	张路霞,左力,徐国宾,等.北京市石景山地区中老年人群中慢性肾脏病的流行病学研究[J].中华肾脏病杂志,2006,22(2):67-71.
[20]	Wang S, Chen R, Liu Q, et al. Prevalence, awareness and treatment of chronic kidney disease among middle-aged and elderly: The China health and retirement longitudinal study[J]. Nephrology (Carlton),2015,20(7):474-484.
[21]	李桂霞.慢性乙型肝炎患者的肾功能早期损害情况及其影响因素研究[J].中国现代药物应用,2017,11(9):27-29.
[22]	韩雪,李菲,宋立文,等.慢性乙型肝炎患者肾功能早期损害的横断面研究[J].天津医药,2015,43(4):375-378.
[23]	徐明亮,熊玉珍,邬小萍,等.肝硬化腹水并发肝肾综合征的危险因素分析[J].实用临床医学,2016,17(8):4-6, 10.
[24]	Cai J, Fan X, Mou L, et al. Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase[J]. Clin J Am Soc Nephrol,2012,7(10):1561-1566.
[25]	Chen J. Epidemiology of hypertension and chronic kidney disease in China[J]. Curr Opin Nephrol Hypertens,2010,19(3):278-282.
[26]	Lin B, Shao L, Luo Q, et al. Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province, Eastern China[J]. BMC Nephrol,2014,15(21):36-42.

项目		例(%)
性别		?
?		?
?	男	4 457(66.87)
?	女	2 208(33.13)
年龄(岁)		?
?	0～	45(0.67)
?	20～	694(10.41)
?	30～	1 792(26.89)
?	40～	1 763(26.45)
?	50～	1 373(20.60)
?	60～	805(12.06)
?	70～	165(2.48)
?	≥ 80	29(0.44)
HBV携带者		607(9.11)
慢性乙型肝炎		4 630(69.47)
乙型肝炎后肝硬化		1 428(21.42)
eGFR(ml/min/1.73 m² )		?
?	< 60	72(1.08)
?	60～90	586(8.79)
?	≥ 90	6 007(90.13)

项目		例(%)
性别		?
?		?
?	男	4 457(66.87)
?	女	2 208(33.13)
年龄(岁)		?
?	0～	45(0.67)
?	20～	694(10.41)
?	30～	1 792(26.89)
?	40～	1 763(26.45)
?	50～	1 373(20.60)
?	60～	805(12.06)
?	70～	165(2.48)
?	≥ 80	29(0.44)
HBV携带者		607(9.11)
慢性乙型肝炎		4 630(69.47)
乙型肝炎后肝硬化		1 428(21.42)
eGFR(ml/min/1.73 m² )		?
?	< 60	72(1.08)
?	60～90	586(8.79)
?	≥ 90	6 007(90.13)

项目		eGFR(ml/min/1.73 m²)		χ ²值	P值
项目		< 60	≥ 60	χ ²值	P值
性别		?	?	0.52	0.473
?	男	51(1.14)	4 406(98.86)	?	?
?	女	21(0.95)	2 187(99.05)	?	?
年龄(岁)		?	?	356.71	< 0.001
?	0～	1(0.04)	2 529(99.96)	?	?
?	40～	18(0.57)	3 118(99.43)	?	?
?	60～	29(3.60)	776(96.40)	?	?
?	70～	17(10.30)	158(89.70)	?	?
?	≥ 80	7(24.13)	22(75.87)	?	?
HBV携带者		1(0.16)	606(99.84)	144.00	< 0.001
慢性乙型肝炎		26(0.59)	4 604(99.41)	?	?
乙型肝炎后肝硬化		45(3.15)	1 383(96.85)	?	?

项目		eGFR(ml/min/1.73 m²)		χ ²值	P值
项目		< 60	≥ 60	χ ²值	P值
性别		?	?	0.52	0.473
?	男	51(1.14)	4 406(98.86)	?	?
?	女	21(0.95)	2 187(99.05)	?	?
年龄(岁)		?	?	356.71	< 0.001
?	0～	1(0.04)	2 529(99.96)	?	?
?	40～	18(0.57)	3 118(99.43)	?	?
?	60～	29(3.60)	776(96.40)	?	?
?	70～	17(10.30)	158(89.70)	?	?
?	≥ 80	7(24.13)	22(75.87)	?	?
HBV携带者		1(0.16)	606(99.84)	144.00	< 0.001
慢性乙型肝炎		26(0.59)	4 604(99.41)	?	?
乙型肝炎后肝硬化		45(3.15)	1 383(96.85)	?	?

指标	eGFR(ml/min/1.73 m²)		χ ²值	P值
指标	< 60	≥ 60	?	?
HBV DNA阳性(> 100 IU/ml)	2(12.5)	228(19.2)	1.93	0.926
ALT异常(> 50 U/L)	7(13.5)	826(22.0)	1.74	0.508
TBil异常(>18.1 μmol/L)	19(36.5)	1 069(28.5)	1.62	0.203
肝硬化	45(62.5)	1 383(20.7)	68.82	< 0.001
高血压	17(23.6)	204(3.1)	93.52	< 0.001
糖尿病	18(25.0)	346(5.2)	53.82	< 0.001

Please choose a citation manager

Content to export